[Extracorporeal circulation with danaparoid sodium for valve replacement in thrombocytopenia induced by type II heparin].
A type II heparin-induced thrombocytopenia (HIT) was diagnosed in a 64-year-old woman at day 20 of intravenous unfractionated heparin (UFH) therapy, given after myocardial infarction treated by angioplasty and intracoronary stent. The infarction was complicated by a mitral insufficiency that led to a mitral valve replacement. Cardiopulmonary bypass was successfully performed with sodium danaparoid (Orgaran), as an alternative to UFH, without thrombotic or haemorrhagic complications and the follow-up was uneventful.
Salmi
L
L
Service d'anesthésie-réanimation, CHU Henri-Mondor, 94010 Créteil, France. zergbh@noos.fr
Leroy-Matheron
C
C
LeBesnerais
P
P
Rosanval
O
O
Duvaldestin
P
P
Gouault-Heilmann
M
M
D000925:Anticoagulants / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004338:Drug Combinations; D005112:Extracorporeal Circulation; D005260:Female; D006350:Heart Valve Prosthesis; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000150:complications / Q000601:surgery*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid
Circulation extracorporelle sous danaparoïde sodique pour remplacement valvulaire au cours d'une thrombopénie induite par l'héparine de type II.